Paul R. Edick files SEC Form 4 disclosures for XERIS PHARMACEUTICALS INC. They have made 14 open-market trades across 3 companies since 2012, most recently 2024-01-31.
CIK 0001531178
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
14 open-market purchases totalling $1.6M since 2012, never a sale. Across 11 scored buys the stock is down 12.5% at ninety days, and 12.0 points behind the S&P over the same stretch.
11 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 55% | 18% | 18% |
| Avg Move | -0.9% | -8.7% | -12.5% |
| Alpha | +0.9% | -7.0% | -12.0% |
| Scored | 11 | 11 | 11 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XERS | BUY | 2023-08-09 | 2023-08-09 | $2.38 | $24K | +0.4% | -11.8% | -21.2% |
| XERS | BUY | 2022-12-13 | 2022-12-14 | $1.45 | $29K | -15.2% | -7.2% | -5.8% |
| XERS | BUY | 2022-05-12 | 2022-05-13 | $1.40 | $140K | +17.6% | -3.9% | +8.7% |
| XERS | BUY | 2021-11-15 | 2021-11-16 | $2.28 | $46K | -19.4% | -12.3% | -4.7% |
| XERS | BUY | 2021-11-11 | 2021-11-12 | $2.08 | $416K | -7.2% | -6.8% | +5.5% |
| XERS | BUY | 2020-12-09 | 2020-12-10 | $4.06 | $41K | +16.6% | +32.0% | -0.2% |
| XERS | BUY | 2020-05-08 | 2020-05-11 | $3.00 | $99K | +19.5% | +32.7% | -7.1% |
| XERS | BUY | 2020-02-14 | 2020-02-18 | $4.15 | $83K | -21.4% | -62.7% | -8.4% |
| XERS | BUY | 2019-11-25 | 2019-11-27 | $8.55 | $307K | +0.2% | -17.0% | -54.9% |
| XERS | BUY | 2019-03-11 | 2019-03-12 | $9.12 | $274K | +5.8% | +0.0% | -13.0% |
| ITRM | BUY | 2018-08-23 | 2018-08-27 | $10.44 | $5K | -7.1% | -38.3% | -36.4% |
| DRTX | BUY | 2014-06-12 | 2014-06-13 | $15.23 | $46K | N/A | N/A | N/A |
| DRTX | BUY | 2013-05-20 | 2013-05-20 | $7.09 | $21K | N/A | N/A | N/A |
| DRTX | BUY | 2012-08-14 | 2012-08-16 | $8.65 | $43K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.